Literature DB >> 30178824

Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression.

D Zhang1, F-L Lv, G-H Wang.   

Abstract

OBJECTIVE: To investigate the effect of hypoxia inducing factor (HIF)-1α on the expression of vascular endothelial growth factor (VEGF) and angiogenesis in diabetic retinopathy. PATIENTS AND METHODS: 8-week healthy SD rats were used for the experiments. Under systemic anesthesia condition, control rats received a saline injection into the left ocular body (control A group), and 2 μl antisense oligonucleotides (ASODN) (10 μmol/L) into right eye (control B group). Model rats received a saline injection into the left eye (model A group), and 2 μl ASODN (10 μmol/L) into the right eye (model B group). Rats received an intraocular injection of HIF-1α ASODN for 2, 4, and 6 weeks (A1, A2, A3, B1, B2, B3, respectively). Retinal vessel development was observed by ADP staining. Vascular endothelial cells penetrating retinal inner membrane were counted. Immunohistochemistry was used to detect expressions of VEGF and HIF-1α proteins in the retina.
RESULTS: Prominent angiogenesis and hyperplasia were found in model A group. Relatively fewer newly formed vessels were shown in model group B. However, no significant change of retinal vascular morphology was presented in control group. Of note, the vascular endothelial cell counts, VEGF and HIF-1α contents were significantly increased in model group (p < 0.05). After treatment with HIF-1α ASODN, lower endothelial cell counts was found in model B group (p < 0.05 comparing to model A). VEGF expression in model B group was significantly decreased, among which, model B3 was observed with lower cell counts than model B1 or B2 (p < 0.05 comparing to model A). Injection of HIF-1α ASODN significantly suppressed HIF-1α level in model B in a time-dependent manner.
CONCLUSIONS: Retinal angiogenesis is closely related with increasing level of HIF-1α. Inhibition of HIF-1α suppressed VEGF expression and deterred angiogenesis in a time-dependent manner. This provided novel insights for treating diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178824     DOI: 10.26355/eurrev_201808_15699

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  29 in total

1.  β-elemene down-regulates HIF-lα, VEGF and iNOS in human retinal pigment epithelial cells under high glucose conditions.

Authors:  Yun Zhou; Jun Chen; Li-Hua Li; Lei Chen
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

2.  Network pharmacology and molecular docking study on the active ingredients of qidengmingmu capsule for the treatment of diabetic retinopathy.

Authors:  Mingxu Zhang; Jiawei Yang; Xiulan Zhao; Ying Zhao; Siquan Zhu
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

Review 3.  HIF-1α in Osteoarthritis: From Pathogenesis to Therapeutic Implications.

Authors:  Chu-Yang Zeng; Xi-Feng Wang; Fu-Zhou Hua
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

4.  Recombinant human erythropoietin accelerated the proliferation of non-small cell lung cancer cell lines and reduced the expression of VEGF, HIF-1α, and PD-L1 under a simulated hypoxic environment in vitro.

Authors:  Yajing Zhang; Yangchun Feng; Xiaojie Sun
Journal:  Chronic Dis Transl Med       Date:  2022-03-31

Review 5.  Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.

Authors:  Yi-Fen Lai; Ting-Yi Lin; Pin-Kuan Ho; Yi-Hao Chen; Yu-Chuan Huang; Da-Wen Lu
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

6.  Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.

Authors:  Tadao Akizawa; Manabu Iwasaki; Yusuke Yamaguchi; Yoshikatsu Majikawa; Michael Reusch
Journal:  J Am Soc Nephrol       Date:  2020-06-03       Impact factor: 10.121

7.  Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.

Authors:  Yasir J Sepah; Quan Dong Nguyen; Yusuke Yamaguchi; Tetsuro Otsuka; Yoshikatsu Majikawa; Michael Reusch; Tadao Akizawa
Journal:  Kidney Int Rep       Date:  2022-01-19

Review 8.  Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.

Authors:  Neil S Sanghani; Volker H Haase
Journal:  Adv Chronic Kidney Dis       Date:  2019-07       Impact factor: 3.620

9.  Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.

Authors:  Tadao Akizawa; Manabu Iwasaki; Tetsuro Otsuka; Yusuke Yamaguchi; Michael Reusch
Journal:  Kidney Int Rep       Date:  2021-04-17

10.  HIF-1α as a Target Molecule in the Use of Triazino-Indole Derivative on the Acoustic Trauma Model.

Authors:  Vladimir L Pastushenkov; Leonid G Buynov; Maksim S Kuznetsov; Vladimir V Dvorianchikov; Lev A Glaznikov; Aleksandr L Pastushenkov
Journal:  Audiol Res       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.